Your browser doesn't support javascript.
loading
Peak functional ability and age at loss of ambulation in Duchenne muscular dystrophy.
Zambon, Alberto A; Ayyar Gupta, Vandana; Ridout, Deborah; Manzur, Adnan Y; Baranello, Giovanni; Trucco, Federica; Muntoni, Francesco.
Affiliation
  • Zambon AA; Dubowitz Neuromuscular Centre, UCL Great Ormond Street Institute of Child Health & Great Ormond Street Hospital, London, UK.
  • Ayyar Gupta V; Neuromuscular Repair Unit, Institute of Experimental Neurology (InSpe), Division of Neuroscience, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Ridout D; Dubowitz Neuromuscular Centre, UCL Great Ormond Street Institute of Child Health & Great Ormond Street Hospital, London, UK.
  • Manzur AY; Population, Policy and Practice Research and Teaching Department, UCL Great Ormond Street Institute of Child Health, London, UK.
  • Baranello G; NIHR Great Ormond Street Hospital Biomedical Research Centre, London, UK.
  • Trucco F; Dubowitz Neuromuscular Centre, UCL Great Ormond Street Institute of Child Health & Great Ormond Street Hospital, London, UK.
  • Muntoni F; NIHR Great Ormond Street Hospital Biomedical Research Centre, London, UK.
Dev Med Child Neurol ; 64(8): 979-988, 2022 08.
Article in En | MEDLINE | ID: mdl-35385138
AIM: To correlate the North Star Ambulatory Assessment (NSAA) and timed rise from floor (TRF) recorded at age of expected peak with age at loss of ambulation (LOA) in Duchenne muscular dystrophy (DMD). METHOD: Male children with DMD enrolled in the UK North Start Network database were included according to the following criteria: follow-up longer than 3 years, one NSAA record between 6 years and 7 years 6 months (baseline), at least one visit when older than 8 years. Data about corticosteroid treatment, LOA, genotype, NSAA, and TRF were analysed. Age at LOA among the different groups based on NSAA and TRF was determined by log-rank tests. Cox proportional hazard models were used for multivariable analysis. RESULTS: A total of 293 patients from 13 different centres were included. Mean (SD) age at first and last visit was 5 years 6 months (1 year 2 months) and 12 years 8 months (2 years 11 months) (median follow-up 7 years 4 months). Higher NSAA and lower TRF at baseline were associated with older age at LOA (p<0.001). Patients scoring NSAA 32 to 34 had a probability of 0.61 of being ambulant when older than 13 years compared with 0.34 for those scoring 26 to 31. In multivariable analysis, NSAA, TRF, and corticosteroid daily regimen (vs intermittent) were all independently associated with outcome (p=0.01). INTERPRETATION: Higher functional abilities at peak are associated with older age at LOA in DMD. This information is important for counselling families. These baseline measures should also be considered when designing clinical trials.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Muscular Dystrophy, Duchenne Type of study: Prognostic_studies Limits: Child / Humans / Male Language: En Journal: Dev Med Child Neurol Year: 2022 Document type: Article Country of publication: United kingdom

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Muscular Dystrophy, Duchenne Type of study: Prognostic_studies Limits: Child / Humans / Male Language: En Journal: Dev Med Child Neurol Year: 2022 Document type: Article Country of publication: United kingdom